USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Jul 27, 2022 | Jun 2022 | $-1.91 | - | $-1.86 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Jul 27, 2022 | Jun 2022 | $43.45M | - | $27.30M |
Blueprint Medicines Corporation's next earnings date is Wednesday, Jul 27, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Jun 2022 | 14 | $-1.91 | $-2.32 | $-1.56 |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 14 | $-7.60 | $-9.02 | $-6.65 |
| Dec 2023 | 14 | $-5.69 | $-7.81 | $-3.62 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Jun 2022 | 2 / 1 | $-1.86 | $-1.84 | $-1.78 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 2 / 1 | $-7.38 | $-7.35 | $-6.94 |
| Dec 2023 | 1 / 1 | $-5.52 | $-5.44 | $-4.30 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|---|---|---|---|
| Jun 2022 | 13 | $43.45M | $27.70M | $66.40M |
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 14 | $190.44M | $173.20M | $199.52M |
| Dec 2023 | 14 | $350.10M | $252.50M | $546.80M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| May 3, 2022 | Mar 2022 | $-1.90 | - | - |
| Feb 16, 2022 | Dec 2021 | $-1.65 | $-5.40 | -227.27% |
| Oct 28, 2021 | Sep 2021 | $-1.63 | $-2.00 | -22.70% |
| Jul 29, 2021 | Jun 2021 | $-1.81 | $-1.86 | -2.86% |
| Apr 29, 2021 | Mar 2021 | $-1.85 | $-1.72 | 6.98% |
| Feb 17, 2021 | Dec 2020 | $-1.59 | $-1.53 | 3.62% |
| Oct 29, 2020 | Sep 2020 | $9.36 | $11.16 | 19.27% |
| Jul 30, 2020 | Jun 2020 | $-2.12 | $-2.28 | -7.31% |
| May 6, 2020 | Mar 2020 | $-2.16 | $-2.11 | 2.44% |
| Feb 13, 2020 | Dec 2019 | $-1.76 | $-1.35 | 23.20% |
| Nov 5, 2019 | Sep 2019 | $-2.19 | $-1.93 | 11.91% |
| Aug 1, 2019 | Jun 2019 | $-1.95 | $-2.04 | -4.39% |
| May 9, 2019 | Mar 2019 | $-1.87 | $-1.98 | -5.79% |
| Feb 26, 2019 | Dec 2018 | $-1.77 | $-1.83 | -3.20% |
| Oct 30, 2018 | Sep 2018 | $-1.57 | $-1.66 | -5.73% |
| Aug 1, 2018 | Jun 2018 | $-1.32 | $-0.62 | 52.85% |
| May 2, 2018 | Mar 2018 | $-1.10 | $-1.29 | -17.27% |
| Feb 21, 2018 | Dec 2017 | $-1.07 | $-1.23 | -14.95% |
| Oct 31, 2017 | Sep 2017 | $-0.89 | $-0.96 | -8.39% |
| Aug 2, 2017 | Jun 2017 | $-0.78 | $-0.86 | -10.72% |
| May 3, 2017 | Mar 2017 | $-0.76 | $-0.84 | -11.26% |
| Mar 9, 2017 | Dec 2016 | $-0.77 | $-0.75 | 2.18% |
| Nov 10, 2016 | Sep 2016 | $-0.79 | $-0.62 | 21.52% |
| Aug 9, 2016 | Jun 2016 | $-0.73 | $-0.70 | 3.58% |
| May 10, 2016 | Mar 2016 | $-0.76 | $-0.57 | 25.00% |
| Mar 11, 2016 | Dec 2015 | $-0.53 | $-0.58 | -9.43% |
| Nov 9, 2015 | Sep 2015 | $-0.53 | $-0.47 | 11.32% |
| Aug 10, 2015 | Jun 2015 | $-0.52 | $-0.81 | -55.77% |
| May 5, 2015 | Mar 2015 | $-2.11 | $-8.23 | -290.05% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Feb 16, 2022 | Dec 2021 | $-6.93 | $-10.98 | - |
| Feb 17, 2021 | Dec 2020 | $5.48 | $5.24 | -4.38% |
| Feb 13, 2020 | Dec 2019 | $-7.59 | $-7.30 | - |
| Feb 26, 2019 | Dec 2018 | $-5.33 | $-5.40 | - |
| Feb 21, 2018 | Dec 2017 | $-3.79 | $-3.89 | - |
| Mar 9, 2017 | Dec 2016 | - | $-2.64 | - |
| Mar 11, 2016 | Dec 2015 | - | $-10.09 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| May 3, 2022 | Mar 2022 | $36.65M | - | - |
| Feb 16, 2022 | Dec 2021 | $102.69M | $107.02M | 1.04% |
| Oct 28, 2021 | Sep 2021 | $42.47M | $24.19M | 0.57% |
| Jul 29, 2021 | Jun 2021 | $27.30M | $27.30M | 1.00% |
| Apr 29, 2021 | Mar 2021 | $17.25M | $21.58M | 1.25% |
| Feb 17, 2021 | Dec 2020 | $29.24M | $34.11M | 1.17% |
| Oct 29, 2020 | Sep 2020 | $631.57M | $745.12M | 1.18% |
| Jul 30, 2020 | Jun 2020 | $6.94M | $8.34M | 1.20% |
| May 6, 2020 | Mar 2020 | $5.44M | $6.17M | 1.13% |
| Feb 13, 2020 | Dec 2019 | $26.07M | $51.53M | 1.98% |
| Nov 5, 2019 | Sep 2019 | $2.59M | $9.14M | 3.53% |
| Aug 1, 2019 | Jun 2019 | $1.98M | $5.11M | 2.58% |
| May 9, 2019 | Mar 2019 | $1.70M | $730.00K | 0.43% |
| Feb 26, 2019 | Dec 2018 | $1.68M | $1.03M | 0.61% |
| Oct 30, 2018 | Sep 2018 | $6.86M | $1.09M | 0.16% |
| Aug 1, 2018 | Jun 2018 | $2.28M | $41.44M | 18.18% |
| May 2, 2018 | Mar 2018 | $2.77M | $954.00K | 0.34% |
| Feb 21, 2018 | Dec 2017 | $5.28M | $1.63M | 0.31% |
| Oct 31, 2017 | Sep 2017 | $5.36M | $8.07M | 1.51% |
| Aug 2, 2017 | Jun 2017 | $5.96M | $5.89M | 0.99% |
| May 3, 2017 | Mar 2017 | - | $5.84M | - |
| Mar 9, 2017 | Dec 2016 | - | $7.69M | - |
| Nov 10, 2016 | Sep 2016 | - | $6.16M | - |
| Aug 9, 2016 | Jun 2016 | - | $7.07M | - |
| May 10, 2016 | Mar 2016 | - | $6.86M | - |
| Mar 11, 2016 | Dec 2015 | - | $4.63M | - |
| Nov 9, 2015 | Sep 2015 | - | $3.43M | - |
| Aug 10, 2015 | Jun 2015 | - | $2.69M | - |
| May 5, 2015 | Mar 2015 | - | $652.00K | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Feb 16, 2022 | Dec 2021 | $176.49M | $180.08M | 2.03% |
| Feb 17, 2021 | Dec 2020 | $787.53M | $793.74M | 0.79% |
| Feb 13, 2020 | Dec 2019 | $41.02M | $66.51M | 62.15% |
| Feb 26, 2019 | Dec 2018 | $45.23M | $44.52M | -1.57% |
| Feb 21, 2018 | Dec 2017 | $24.67M | $21.43M | -13.15% |
| Mar 9, 2017 | Dec 2016 | - | $27.77M | - |
| Mar 11, 2016 | Dec 2015 | - | $11.40M | - |
BPMC's next earnings date is Wednesday, Jul 27, 2022 for the fiscal quarter ending Jun 30, 2022.
According to analysts, the average EPS estimation for Blueprint Medicines Corporation's next quarterly earnings is $-1.91, with a low EPS estimation of $-2.32, and a high estimation of $-1.56.
Over the last 1 month, EPS estimates have seen 2 upward revisions and 1 downward. The EPS 1 month trend is $-1.86, the last 2 month trend is $-1.84, and the 3 month trend is $-1.78.
Based on analysts, the average revenue estimation is $43.45M, with a low revenue estimation of $27.70M, and a high estimation of $66.40M.
Blueprint Medicines Corporation's previous earnings date was May 3, 2022 for its fiscal quarter ended Mar 31, 2022.
Blueprint Medicines Corporation's previous annual earnings date was Feb 16, 2022 for its fiscal year ended Dec 31, 2021.
BPMC's earnings per share (EPS) was $-10.98, missing the consensus analysts forecast of $-6.93 by 58.44% , and lower than the previous year's EPS (Dec 2020) by -309.54%.
Revenues were $180.08M, better than the forecast of $176.49M by 2.03%, and down by -77.31% from previous year's revenue.
The company reported a net income of $-644.09M.
Blueprint Medicines Corporation reported a free cash flow of $-559.89M for its fiscal year, compared to $383.88M a year ago.
The company ended the fiscal year with $111.41M in total debt, an increase of 24.33% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
